HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

fluperlapine

structure given in first source

Also Known As:

3-fluoro-6-(4-methylpiperazinyl)-11H-dibenz(b,e)azepine; NB 106-689

Networked: 15 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Dibenzazepines: 4
      - fluperlapine: 15

Experts

1.	Meyer, J M: 1 article (08/2001)
2.	Gardner, I: 1 article (03/2000)
3.	Lai, W G: 1 article (03/2000)
4.	Uetrecht, J P: 1 article (03/2000)
5.	Zahid, N: 1 article (03/2000)

Related Diseases

1.	Movement Disorders (Movement Disorder) 01/01/1984 - "The effects in movement disorders found in this study may imply that fluperlapine is less liable than traditional neuroleptics to induce acute extrapyramidal side effects and tardive dyskinesia and is particularly beneficial in the treatment of patients vulnerable to neurological side-effects."
2.	Tardive Dyskinesia 01/01/1984 - "Fluperlapine in tardive dyskinesia and parkinsonism." 01/01/1984 - "The effects in movement disorders found in this study may imply that fluperlapine is less liable than traditional neuroleptics to induce acute extrapyramidal side effects and tardive dyskinesia and is particularly beneficial in the treatment of patients vulnerable to neurological side-effects." 01/01/1984 - "Fluperlapine, a new clozapine-like neuroleptic drug with weak affinity for dopamine receptors, was evaluated in a blind, placebo controlled trial in 11 patients with stable hyperkinesia (ten with tardive dyskinesia (TD) and one with spontaneous dyskinesia). "
3.	Psychotic Disorders (Schizoaffective Disorder) 01/01/1985 - "Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine." 01/01/1985 - "A total of 13 patients with drug-induced psychosis in Parkinson's disease were treated with two non-classical neuroleptics-clozapine and fluperlapine. " 12/01/1995 - "We propose that since N-methyl-D-aspartate receptor hypofunction can cause psychosis in humans and corticolimbic neurodegenerative changes in the rat brain, and since these changes are prevented by certain antipsychotic drugs, including atypical neuroleptic agents (clozapine, olanzapine, fluperlapine), a better understanding of the N-methyl-D-aspartate receptor hypofunction mechanism and ways of preventing its neurodegenerative consequences in the rat brain may lead to improved pharmacotherapy in schizophrenia."
4.	Schizophrenia (Dementia Praecox) 12/01/1995 - "We propose that since N-methyl-D-aspartate receptor hypofunction can cause psychosis in humans and corticolimbic neurodegenerative changes in the rat brain, and since these changes are prevented by certain antipsychotic drugs, including atypical neuroleptic agents (clozapine, olanzapine, fluperlapine), a better understanding of the N-methyl-D-aspartate receptor hypofunction mechanism and ways of preventing its neurodegenerative consequences in the rat brain may lead to improved pharmacotherapy in schizophrenia."
5.	Dyskinesias (Dyskinesia) 01/01/1984 - "Fluperlapine, a new clozapine-like neuroleptic drug with weak affinity for dopamine receptors, was evaluated in a blind, placebo controlled trial in 11 patients with stable hyperkinesia (ten with tardive dyskinesia (TD) and one with spontaneous dyskinesia). "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Clozapine (Clozaril)
3.	Olanzapine (Zyprexa)
4.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
5.	Dopamine Receptors (Dopamine Receptor)
6.	fluperlapine
7.	Cholinergic Antagonists (Anticholinergics)
8.	Haloperidol (Haldol)
9.	Prolactin
10.	Oxides

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Induced Hyperthermia (Thermotherapy)